Results for ccr translation from English to Maltese

clinical complete response (ccr) %
rispons kliniku sħiħ (ccr)

aza = 82, ccr = 113 proportion surviving
aza = 82, ccr = 113 proporzjon li għexu

vidaza plus bsc (n=241) was compared to ccr.
vidaza flimkien ma’ bsc (n=241) ġie pparagunat ma’ ccr.

the individual baseline parameters were comparable between the vidaza and ccr groups.
il-parametri individwali fil-linja bażi kienu komparabbli bejn il-gruppi ta’ vidaza u ccr.

patients were pre-selected by their physician to 1 of the 3 ccr prior to randomisation.
il- pazjenti ntgħażlu minn qabel mit-tabib tagħhom għal 1 mit-3 ccr qabel ir-randomisation.

whereas provision should be made for member states to send the commission a copy of the information they send the ccr in accordance with this rgulation,
billi l-istati membri għandhom jibgħatu lill-kummissjoni kopja ta' l-informazzjoni li huma jibgħatu lis-ccr skond dan ir-regolament,

patients with given number of index/indicator lesion responses (ccr or pr)
pazjenti b’numru fiss ta’ risponsi ta’ leżjonijiet indiċi/indikaturi (ccr jew pr)

in patients with one or more cytogenetic abnormalities at baseline, the percentage of patients with a major cytogenetic response was similar in the azacitidine and combined ccr groups.
f’pazjenti b’anormalità ċitoġenika waħda jew aktar fil-linja bażi, il-perċentwali ta’ pazjenti b’rispons ċitoġeniku maġġuri kien simili fil-gruppi kkurati b’azacitidine u b’ccr kombinat.

the two-year survival rates were 50.8 % in patients receiving azacitidine versus 26.2 % in patients receiving ccr (p < 0.0001).
ir-rati tas-sopravivenza fuq medda ta’ sentejn kienu 50.8% f’pazjenti li kienu qed jirċievu azacitidine kontra 26.2% f’pazjenti li kienu qed jirċievu ccr (p < 0.0001).